SEEN: Patient Navigator Intervention for Diabetic Retinopathy

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05188703
Collaborator
(none)
60
1
1
40.2
1.5

Study Details

Study Description

Brief Summary

This is a pilot study of a patient navigator intervention for people living with diabetes and at high risk of diabetic blindness. The investigators are assessing the feasibility and acceptability of the intervention in preparation for a clinical trial.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Patient Navigation
N/A

Detailed Description

Evidence-based treatment for Diabetic retinopathy (DR) established 30 years ago decreases the likelihood of blindness by 50%. Outcomes are even better now with emerging therapies and technology. Diabetes remains the leading cause of new cases of legal blindness. This study is significant because it investigates the gap between published guidelines and the population that continues to go blind despite well-established recommendations for screening. Our current model of screening for DR screens much of the population appropriately. There is an opportunity to improve DR screening by timely identification of persons at risk for preventable blindness. DR disproportionately impacts Non-Hispanic Blacks, Latinos, Native Americans, and lower socioeconomic communities. Racial and ethnic minorities are less likely to be screened for DR, have a higher prevalence of disease, and more severe disease. There is not a clear path toward decreasing these disparities beyond these data. This study addresses barriers to the implementation of evidenced-based treatment protocols by identifying modifiable patient and population-level challenges and building an intervention informed by community members and national data. It is a direct response to the "population health imperative" described by the National Academies of Science, Engineering, and Medicine. Our study answers the National Eye Institute's Strategic Plan request to evaluate disparities by identifying barriers that prevent optimal treatment. It is aligned with the NEI's mission to support research and training with respect to the preservation of sight. The National Institute on Minority Health and Health Disparities Research Framework provides the conceptual foundation for our work. Our proposal identifies facets of the biologic, built, and sociocultural environments of the national population with undiagnosed DR. The national analysis informs a local individual-level intervention that addresses determinants associated with DR screening. The scientific premise of this study is the forty percent of persons with diabetes not screened despite established sight-saving treatment, the known disparities in screening for DR, and the increased prevalence of sight-threatening DR in Black, Latino, Native, and lower income Americans.

Primary Objective The primary objective of this study is to design and pilot a patient navigator program to increase screening for DR in a high-risk population.

Secondary Objective To determine the feasibility and accessibility of a patient navigation program for persons at high-risk for DR.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a single arm study. All participants will receive the intervention.This is a single arm study. All participants will receive the intervention.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Undiagnosed Diabetic Retinopathy: Using Participatory Science to Design an Intervention for Patients at High-Risk for Blindness
Anticipated Study Start Date :
Jul 25, 2022
Anticipated Primary Completion Date :
Jan 14, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention arm

Intervention consists of standard of care eye exam and enrollment in a patient navigation program.

Behavioral: Patient Navigation
Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.

Outcome Measures

Primary Outcome Measures

  1. Number of participant who had baseline eye exam [18 months]

    The number of participants who had their baseline eye exam will be determined using the electronic health record

  2. Number of participants who completed a follow-up eye exam 12+ months after baseline eye exam [up to 18 month]

    The number of participants who completed a follow-up eye exam 12+ months after baseline eye exam will be determined using the electronic health record

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults aged 18 and over

  • Diagnosis of diabetes and record of diagnosis in YNHHS EPIC

  • English-speaking

  • No documented eye examination within 1 year of study enrollment

  • High risk for diabetic retinopathy based on risk calculator evaluation

Exclusion Criteria:
  • Documented eye exam in the past year

  • Not high risk for diabetic retinopathy

  • Diabetes diagnosis not recorded in EPIC

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yale School of Medicine New Haven Connecticut United States 06511

Sponsors and Collaborators

  • Yale University

Investigators

  • Principal Investigator: Kristen Nwanyanwu, MD, MHS, Yale School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT05188703
Other Study ID Numbers:
  • 2000031731
First Posted:
Jan 12, 2022
Last Update Posted:
Jul 22, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yale University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 22, 2022